Dependovirus – Talk Bio

Rocket Pharmaceuticals Cuts 30% of Staff, Refocuses on Heart Gene Therapies

16 hours ago talkbio0Tagged 30%, Anemia, BAG3-associated, cardiovascular gene therapy, Deficiency of pyruvate kinase, Dependovirus, Financial cost, Glycogen Storage Disease Type IIb, Kresladi, layoffs, PKP2-associated cardiomyopathy, restructuring, Rocket

Rocket Pharmaceuticals; layoffs; restructuring; 30% workforce reduction; cardiovascular gene therapy; adeno-associated virus (AAV); Danon disease; PKP2-associated cardiomyopathy; BAG3-associated dilated cardiomyopathy; operating cost reduction; Fanconi Anemia; Pyruvate Kinase Deficiency; KRESLADI

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

3 months ago talkbio0Tagged Dependovirus, gene therapy, Industry, Partnership, research, Safety, Transfer RNA

gene therapy, Dependovirus, Transfer RNA, Partnership, Industry, research, Safety

Atsena reels in $150M to advance work on ocular gene therapies

4 months ago talkbio0Tagged Atsena, ATSN-101, ATSN-201, Blindness, Cloning Vectors, Dependovirus, Hereditary, Retinal Diseases, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration

Atsena, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration, Dependovirus, Cloning Vectors, Hereditary, Retinal Diseases, Blindness, ATSN-201, ATSN-101

Capsida and AbbVie’s Gene Therapy Collaboration Yields Promising Results for Eye Diseases

7 months ago talkbio0Tagged AbbVie, Capsida Biotherapeutics, Dependovirus, gene therapy, genetic medicines, Ophthalmology specialty, strategic collaboration

Capsida Biotherapeutics, AbbVie, gene therapy, eye diseases, strategic collaboration, adeno-associated virus (AAV) engineering platform, ophthalmology, genetic medicines.